Stephen B Fox

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6055926/publications.pdf

Version: 2024-02-01

319 papers	31,621 citations	5248 83 h-index	4978 167 g-index
326 all docs	326 docs citations	326 times ranked	40003 citing authors

#	Article	IF	Citations
1	Gene Expression Profiling in Breast Cancer: Understanding the Molecular Basis of Histologic Grade To Improve Prognosis. Journal of the National Cancer Institute, 2006, 98, 262-272.	3.0	1,824
2	Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 10393-10398.	3.3	1,796
3	Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome. Clinical Cancer Research, 2008, 14, 5198-5208.	3.2	1,312
4	Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nature Medicine, 2009, 15, 907-913.	15.2	1,261
5	Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncology, The, 2012, 13, 1011-1019.	5.1	1,176
6	BRCA Mutation Frequency and Patterns of Treatment Response in BRCA Mutationâ€“Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group. Journal of Clinical Oncology, 2012, 30, 2654-2663.	0.8	1,018
7	Quantification of Regulatory T Cells Enables the Identification of High-Risk Breast Cancer Patients and Those at Risk of Late Relapse. Journal of Clinical Oncology, 2006, 24, 5373-5380.	0.8	997
8	Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis. Nature Medicine, 2018, 24, 986-993.	15.2	689
9	Prognostic Significance of p16^{INK4A} and Human Papillomavirus in Patients With Oropharyngeal Cancer Treated on TROG 02.02 Phase III Trial. Journal of Clinical Oncology, 2010, 28, 4142-4148.	0.8	679
10	Breast cancer prognostic classification in the molecular era: the role of histological grade. Breast Cancer Research, 2010, 12, 207.	2.2	650
11	Lymphangiogenesis and lymphatic vessel remodelling in cancer. Nature Reviews Cancer, 2014, 14, 159-172.	12.8	621
12	Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists. Modern Pathology, 2011, 24, 157-167.	2.9	545
13	Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Nonâ€“Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors. Advances in Anatomic Pathology, 2017, 24, 311-335.	2.4	530
14	Pathology of Breast and Ovarian Cancers among BRCA1 and BRCA2 Mutation Carriers: Results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 134-147.	1.1	513
15	Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research. Advances in Anatomic Pathology, 2017, 24, 235-251.	2.4	469
16	MET Amplification Identifies a Small and Aggressive Subgroup of Esophagogastric Adenocarcinoma With Evidence of Responsiveness to Crizotinib. Journal of Clinical Oncology, 2011, 29, 4803-4810.	0.8	404
17	Quantitation and prognostic value of breast cancer angiogenesis: Comparison of microvessel density, Chalkley count, and computer image analysis. Journal of Pathology, 1995, 177, 275-283.	2.1	396
18	Thymidine phosphorylase is angiogenic and promotes tumor growth.. Proceedings of the National Academy of Sciences of the United States of America, 1995, 92, 998-1002.	3.3	356

#	Article	IF	Citations
19	Phyllodes tumours of the breast: a consensus review. Histopathology, 2016, 68, 5-21.	1.6	329
20	UV-Associated Mutations Underlie the Etiology of MCV-Negative Merkel Cell Carcinomas. Cancer Research, 2015, 75, 5228-5234.	0.4	270
21	No evidence of clonal somatic genetic alterations in cancer-associated fibroblasts from human breast and ovarian carcinomas. Nature Genetics, 2008, 40, 650-655.	9.4	269
22	Integrated Genome-Wide DNA Copy Number and Expression Analysis Identifies Distinct Mechanisms of Primary Chemoresistance in Ovarian Carcinomas. Clinical Cancer Research, 2009, 15, 1417-1427.	3.2	266
23	The Hippo pathway transcriptional co-activator, YAP, is an ovarian cancer oncogene. Oncogene, 2011, 30, 2810-2822.	2.6	256
24	VEGF-D Promotes Tumor Metastasis by Regulating Prostaglandins Produced by the Collecting Lymphatic Endothelium. Cancer Cell, 2012, 21, 181-195.	7.7	244
25	Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group. Modern Pathology, 2016, 29, 1155-1164.	2.9	230
26	Combined immune checkpoint blockade as a therapeutic strategy for BRCA1 -mutated breast cancer. Science Translational Medicine, 2017, 9, .	5.8	227
27	Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study. Lancet Oncology, The, 2017, 18, 52-62.	5.1	225
28	Hypoxia-Inducible Factor-1Î± Expression Predicts a Poor Response to Primary Chemoendocrine Therapy and Disease-Free Survival in Primary Human Breast Cancer. Clinical Cancer Research, 2006, 12, 4562-4568.	3.2	223
29	Angiogenesis: pathological, prognostic, and growth-factor pathways and their link to trial design and anticancer drugs. Lancet Oncology, The, 2001, 2, 278-289.	5.1	222
30	Increased Angiogenesis and Lymphangiogenesis in Inflammatory versus Noninflammatory Breast Cancer by Real-Time Reverse Transcriptase-PCR Gene Expression Quantification. Clinical Cancer Research, 2004, 10, 7965-7971.	3.2	215
31	Sequence artefacts in a prospective series of formalin-fixed tumours tested for mutations in hotspot regions by massively parallel sequencing. BMC Medical Genomics, 2014, 7, 23.	0.7	200
32	The angiogenic switch for vascular endothelial growth factor (VEGF)-A, VEGF-B, VEGF-C, and VEGF-D in the adenoma-carcinoma sequence during colorectal cancer progression. Journal of Pathology, 2003, 200, 183-194.	2.1	191
33	First international consensus on the methodology of lymphangiogenesis quantification in solid human tumours. British Journal of Cancer, 2006, 95, 1611-1625.	2.9	185
34	High resolution melting analysis for rapid and sensitive EGFR and KRAS mutation detection in formalin fixed paraffin embedded biopsies. BMC Cancer, 2008, 8, 142.	1.1	184
35	The key hypoxia regulated gene CAIX is upregulated in basal-like breast tumours and is associated with resistance to chemotherapy. British Journal of Cancer, 2009, 100, 405-411.	2.9	180
36	Randomized Phase II Trial of Letrozole and Letrozole Plus Low-Dose Metronomic Oral Cyclophosphamide As Primary Systemic Treatment in Elderly Breast Cancer Patients. Journal of Clinical Oncology, 2006, 24, 3623-3628.	0.8	178

#	Article	IF	Citations
37	Platelet-derived endothelial cell growth factor/thymidine phosphorylase expression in normal tissues: An immunohistochemical study. Journal of Pathology, 1995, 176, 183-190.	2.1	175
38	Sensitization of BCL-2â€“expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 2766-2771.	3.3	173
39	Tumor angiogenesis in node-negative breast carcinomas ? relationship with epidermal growth factor receptor, estrogen receptor, and survival. Breast Cancer Research and Treatment, 1994, 29, 109-116.	1.1	167
40	Loss of <scp>CDKN</scp>2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the <scp>CDK</scp>4/6 inhibitor <scp>PD</scp>0332991 in melanoma cell lines. Pigment Cell and Melanoma Research, 2014, 27, 590-600.	1.5	165
41	The Bioreductive Prodrug PR-104A Is Activated under Aerobic Conditions by Human Aldo-Keto Reductase 1C3. Cancer Research, 2010, 70, 1573-1584.	0.4	153
42	Inflammatory breast cancer shows angiogenesis with high endothelial proliferation rate and strong E-cadherin expression. British Journal of Cancer, 2003, 88, 718-725.	2.9	151
43	Vascular endothelial growth factor(VEGF)-A and platelet-derived growth factor(PDGF) play a central role in the pathogenesis of digital clubbing. Journal of Pathology, 2004, 203, 721-728.	2.1	149
44	Constitutional Methylation of the BRCA1 Promoter Is Specifically Associated with BRCA1 Mutation-Associated Pathology in Early-Onset Breast Cancer. Cancer Prevention Research, 2011, 4, 23-33.	0.7	147
45	Breast tumour angiogenesis. Breast Cancer Research, 2007, 9, 216.	2.2	146
46	Recruitment of regulatory T cells is correlated with hypoxia-induced CXCR4 expression, and is associated with poor prognosis in basal-like breast cancers. Breast Cancer Research, 2011, 13, R47.	2.2	146
47	PROGNOSTIC VALUE OF ANGIOGENESIS IN OPERABLE NON-SMALL CELL LUNG CANCER. , 1996, 179, 80-88.		144
48	The Androgen Receptor Is Significantly Associated with Vascular Endothelial Growth Factor and Hypoxia Sensing via Hypoxia-Inducible Factors HIF-1a, HIF-2a, and the Prolyl Hydroxylases in Human Prostate Cancer. Clinical Cancer Research, 2005, 11, 7658-7663.	3.2	144
49	The epidermal growth factor receptor as a prognostic marker: Results of 370 patients and review of 3009 patients. Breast Cancer Research and Treatment, 1994, 29, 41-49.	1.1	143
50	The path to a better biomarker: application of a risk management framework for the implementation of PDâ€Ł1 and TILs as immunoâ€•oncology biomarkers in breast cancer clinical trials and daily practice. Journal of Pathology, 2020, 250, 667-684.	2.1	142
51	Quantification and localisation of FOXP3+ T lymphocytes and relation to hepatic inflammation during chronic HCV infection. Journal of Hepatology, 2007, 47, 316-324.	1.8	140
52	Testing for ALK rearrangement in lung adenocarcinoma: a multicenter comparison of immunohistochemistry and fluorescent in situ hybridization. Modern Pathology, 2013, 26, 1545-1553.	2.9	138
53	Lobular Neoplasia of the Breast Revisited With Emphasis on the Role of E-Cadherin Immunohistochemistry. American Journal of Surgical Pathology, 2013, 37, e1-e11.	2.1	137
54	Immunomodulation of FOXP3+ Regulatory T Cells by the Aromatase Inhibitor Letrozole in Breast Cancer Patients. Clinical Cancer Research, 2009, 15, 1046-1051.	3.2	133

#	Article	IF	Citations
55	Histological quantitation of tumour angiogenesis. Apmis, 2004, 112, 413-430.	0.9	132
56	The Role of the Tumor Vasculature in the Host Immune Response: Implications for Therapeutic Strategies Targeting the Tumor Microenvironment. Frontiers in Immunology, 2016, 7, 621.	2.2	132
57	Comparison of Four PD-L1 Immunohistochemical Assays in Lung Cancer. Journal of Thoracic Oncology, 2018, 13, 367-376.	0.5	127
58	Bloodâ€based detection of <scp>RAS</scp> mutations to guide antiâ€<scp>EGFR</scp> therapy in colorectal cancer patients: concordance of results from circulating tumor <scp>DNA</scp> and tissueâ€based <scp>RAS</scp> testing. Molecular Oncology, 2017, 11, 208-219.	2.1	125
59	Adrenomedullin and tumour angiogenesis. British Journal of Cancer, 2006, 94, 1-7.	2.9	124
60	HER3 and downstream pathways are involved in colonization of brain metastases from breast cancer. Breast Cancer Research, 2010, 12, R46.	2.2	122
61	TUMOUR ANGIOGENESIS. , 1996, 179, 232-237.		120
62	The Presence of a Fibrotic Focus in Invasive Breast Carcinoma Correlates with the Expression of Carbonic Anhydrase IX and is a Marker of Hypoxia and Poor Prognosis. Breast Cancer Research and Treatment, 2003, 81, 137-147.	1.1	120
63	High resolution melting for mutation scanning of TP53exons 5â€“8. BMC Cancer, 2007, 7, 168.	1.1	119
64	The Subclonal Architecture of Metastatic Breast Cancer: Results from a Prospective Community-Based Rapid Autopsy Program â€œCASCADEâ€• PLoS Medicine, 2016, 13, e1002204.	3.9	119
65	Molecular correlates of platinum response in human highâ€grade serous ovarian cancer patientâ€derived xenografts. Molecular Oncology, 2014, 8, 656-668.	2.1	117
66	Association of Tumor Angiogenesis With Bone Marrow Micrometastases in Breast Cancer Patients. Journal of the National Cancer Institute, 1997, 89, 1044-1049.	3.0	116
67	Phosphorylated ERÎ±, HIF-1Î±, and MAPK Signaling As Predictors of Primary Endocrine Treatment Response and Resistance in Patients With Breast Cancer. Journal of Clinical Oncology, 2009, 27, 227-234.	0.8	116
68	Preoperative Î²-Blockade with Propranolol Reduces Biomarkers of Metastasis in Breast Cancer: A Phase II Randomized Trial. Clinical Cancer Research, 2020, 26, 1803-1811.	3.2	113
69	Tumour-infiltrating lymphocytes and the emerging role of immunotherapy in breast cancer. Pathology, 2017, 49, 141-155.	0.3	112
70	The molecular origin and taxonomy of mucinous ovarian carcinoma. Nature Communications, 2019, 10, 3935.	5.8	110
71	A Multicenter Blinded Study to Evaluate KRAS Mutation Testing Methodologies in the Clinical Setting. Journal of Molecular Diagnostics, 2009, 11, 543-552.	1.2	107
72	Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer. Npj Breast Cancer, 2020, 6, 17.	2.3	106

#	Article	IF	Citations
73	Expression of the cell death genes BNip3 and NIX in ductal carcinomain situ of the breast; correlation of BNip3 levels with necrosis and grade. Journal of Pathology, 2003, 201, 573-580.	2.1	105
74	Distinct Molecular Signature of Inflammatory Breast Cancer by cDNA Microarray Analysis. Breast Cancer Research and Treatment, 2005, 93, 237-246.	1.1	104
75	Decreased Prostate Cancer-Specific Survival of Men with BRCA2 Mutations from Multiple Breast Cancer Families. Cancer Prevention Research, 2011, 4, 1002-1010.	0.7	100
76	Expression of delta-like ligand 4 (Dll4) and markers of hypoxia in colon cancer. British Journal of Cancer, 2009, 101, 1749-1757.	2.9	98
77	Gata-3 Negatively Regulates the Tumor-Initiating Capacity of Mammary Luminal Progenitor Cells and Targets the Putative Tumor Suppressor Caspase-14. Molecular and Cellular Biology, 2011, 31, 4609-4622.	1.1	96
78	Intra- and Interobserver Reproducibility Assessment of PD-L1 Biomarker in Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2017, 23, 4569-4577.	3.2	96
79	Massivelyâ€parallel sequencing assists the diagnosis and guided treatment of cancers of unknown primary. Journal of Pathology, 2013, 231, 413-423.	2.1	94
80	Prognostic Significance of PD-L1+ and CD8+ Immune Cells in HPV+ Oropharyngeal Squamous Cell Carcinoma. Cancer Immunology Research, 2018, 6, 295-304.	1.6	93
81	Expression of the angiopoietins and their receptor Tie2 in human renal clear cell carcinomas; regulation by the von Hippel-Lindau gene and hypoxia. Journal of Pathology, 2002, 198, 502-510.	2.1	88
82	The transcription factor DEC1 (stra13, SHARP2) is associated with the hypoxic response and high tumour grade in human breast cancers. British Journal of Cancer, 2004, 91, 954-958.	2.9	88
83	Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Research, 2016, 18, 15.	2.2	88
84	Ductal Carcinoma In Situ Biology, Biomarkers, and Diagnosis. Frontiers in Oncology, 2017, 7, 248.	1.3	88
85	Subtypes of familial breast tumours revealed by expression and copy number profiling. Breast Cancer Research and Treatment, 2010, 123, 661-677.	1.1	86
86	c-Myc Interacts with Hypoxia to Induce Angiogenesis In vivo by a Vascular Endothelial Growth Factor-Dependent Mechanism. Cancer Research, 2004, 64, 6563-6570.	0.4	85
87	Expression of the Forkhead Transcription Factor FOXP1 Is Associated with Estrogen Receptor Î± and Improved Survival in Primary Human Breast Carcinomas. Clinical Cancer Research, 2004, 10, 3521-3527.	3.2	85
88	Relationship between Epidermal Growth Factor Receptor Status, p16INK4A, and Outcome in Head and Neck Squamous Cell Carcinoma. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 1230-1237.	1.1	84
89	Enhanced RAD21 cohesin expression confers poor prognosis and resistance to chemotherapy in high grade luminal, basal and HER2 breast cancers. Breast Cancer Research, 2011, 13, R9.	2.2	83
90	BNIP3 as a Progression Marker in Primary Human Breast Cancer; Opposing Functions in In situ Versus Invasive Cancer. Clinical Cancer Research, 2007, 13, 467-474.	3.2	81

#	Article	IF	Citations
91	Increased expression of CD44v6 and CD44v3 in ulcerative colitis but not colonic Crohn's disease. Lancet, The, 1995, 345, 1205-1209.	6.3	80
92	Upregulation of basic fibroblast growth factor in breast carcinoma and its relationship to vascular density, oestrogen receptor, epidermal growth factor receptor and survival. Annals of Oncology, 1999, 10, 707-713.	0.6	75
93	Role of carbonic anhydrase IX expression in prediction of the efficacy and outcome of primary epirubicin/tamoxifen therapy for breast cancer. Endocrine-Related Cancer, 2006, 13, 921-930.	1.6	74
94	Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Research, 2011, 13, R110.	2.2	71
95	Comparison of Methods in the Detection of ALK and ROS1 Rearrangements in Lung Cancer. Journal of Thoracic Oncology, 2015, 10, 611-618.	0.5	70
96	Rapid detection of carriers with BRCA1 and BRCA2mutations using high resolution melting analysis. BMC Cancer, 2008, 8, 59.	1.1	69
97	Minichromosome maintenance protein 2 expression in normal kidney and renal cell carcinomas: relationship to tumor dormancy and potential clinical utility. Clinical Cancer Research, 2002, 8, 1075-81.	3.2	68
98	CUP-AI-Dx: A tool for inferring cancer tissue of origin and molecular subtype using RNA gene-expression data and artificial intelligence. EBioMedicine, 2020, 61, 103030.	2.7	67
99	Dual Targeting of CDK4/6 and BCL2 Pathways Augments Tumor Response in Estrogen Receptorâ€“Positive Breast Cancer. Clinical Cancer Research, 2020, 26, 4120-4134.	3.2	65
100	Markers of tumor angiogenesis: clinical applications in prognosis and anti-angiogenic therapy. , 1997, 15, 15-28.		64
101	Role of p53 in the progression of gastric cancer. Oncotarget, 2014, 5, 12016-12026.	0.8	64
102	Frequent activating STAT3 mutations and novel recurrent genomic abnormalities detected in breast implant-associated anaplastic large cell lymphoma. Oncotarget, 2018, 9, 36126-36136.	0.8	62
103	Selective silencing of the hypoxia-inducible factor 1 target gene BNIP3 by histone deacetylation and methylation in colorectal cancer. Oncogene, 2007, 26, 132-141.	2.6	61
104	International Expert Consensus on Primary Systemic Therapy in the Management of Early Breast Cancer: Highlights of the Fourth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2010). Journal of the National Cancer Institute Monographs, 2011, 2011, 147-151.	0.9	61
105	The genomic landscape of phaeochromocytoma. Journal of Pathology, 2015, 236, 78-89.	2.1	61
106	Relationship of the Breast Ductal Carcinoma In Situ Immune Microenvironment with Clinicopathological and Genetic Features. Clinical Cancer Research, 2017, 23, 5210-5217.	3.2	61
107	CITED4 Inhibits Hypoxia-Activated Transcription in Cancer Cells, and Its Cytoplasmic Location in Breast Cancer Is Associated with Elevated Expression of Tumor Cell Hypoxia-Inducible Factor 1Î±. Cancer Research, 2004, 64, 6075-6081.	0.4	60
108	Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancer. British Journal of Cancer, 2013, 108, 1587-1592.	2.9	59

#	Article	IF	Citations
109	Molecular methods for somatic mutation testing in lung adenocarcinoma: EGFR and beyond. Translational Lung Cancer Research, 2015, 4, 126-41.	1.3	59
110	BRCA1 tumours correlate with a HIF-1Î± phenotype and have a poor prognosis through modulation of hydroxylase enzyme profile expression. British Journal of Cancer, 2009, 101, 1168-1174.	2.9	56
111	VEGF-B expression in human primary breast cancers is associated with lymph node metastasis but not angiogenesis. Journal of Pathology, 2001, 193, 325-332.	2.1	55
112	Genotypic and phenotypic analysis of familial male breast cancer shows under representation of the HER2 and basal subtypes in BRCA-associated carcinomas. BMC Cancer, 2012, 12, 510.	1.1	55
113	Mutations in EGFR, BRAF and RAS are rare in triple-negative and basal-like breast cancers from Caucasian women. Breast Cancer Research and Treatment, 2014, 143, 385-392.	1.1	54
114	Nuclear and cytoplasmic expressions of ERÎ²1 and ERÎ²2 are predictive of response to therapy and alters prognosis in familial breast cancers. Breast Cancer Research and Treatment, 2011, 126, 395-405.	1.1	53
115	Differential mechanisms of CDKN2A (p16) alteration in oral tongue squamous cell carcinomas and correlation with patient outcome. International Journal of Cancer, 2014, 135, 887-895.	2.3	53
116	The prognostic value of quantitative angiogenesis in breast cancer and role of adhesion molecule expression in tumor endothelium. Breast Cancer Research and Treatment, 1995, 36, 219-226.	1.1	52
117	Phosphorylated KDR is expressed in the neoplastic and stromal elements of human renal tumours and shuttles from cell membrane to nucleus. Journal of Pathology, 2004, 202, 313-320.	2.1	52
118	Down-Regulation of Phosphatidylinositol 3â€²-Kinase/AKT/Molecular Target of Rapamycin Metabolic Pathway by Primary Letrozole-Based Therapy in Human Breast Cancer. Clinical Cancer Research, 2008, 14, 2673-2680.	3.2	52
119	â€œOvercoming breast cancer drug resistance with mTOR inhibitorsâ€• Could it be a myth or a real possibility in the short-term future?. Breast Cancer Research and Treatment, 2011, 128, 599-606.	1.1	52
120	Relationship of elevated tumour thymidine phosphorylase in node-positive breast carcinomas to the effects of adjuvant CMF. Annals of Oncology, 1997, 8, 271-275.	0.6	51
121	The epidermal growth factor receptor in breast cancer. Journal of Mammary Gland Biology and Neoplasia, 1997, 2, 131-141.	1.0	51
122	Assessing the clinical value of targeted massively parallel sequencing in a longitudinal, prospective population-based study of cancer patients. British Journal of Cancer, 2015, 112, 1411-1420.	2.9	51
123	Apatinib for the treatment of gastric cancer. Expert Review of Gastroenterology and Hepatology, 2016, 10, 1-6.	1.4	51
124	Role of the novel generation of androgen receptor pathway targeted agents in the management of castration-resistant prostate cancer: A literature based meta-analysis of randomized trials. European Journal of Cancer, 2016, 61, 111-121.	1.3	51
125	The cancer genetics and pathology of male breast cancer. Histopathology, 2016, 68, 110-118.	1.6	51
126	Breast cancer angiogenesis â€” new approaches to therapy via antiangiogenesis, hypoxic activated drugs, and vascular targeting. Breast Cancer Research and Treatment, 1996, 38, 97-108.	1.1	50

#	Article	IF	Citations
127	E6AP ubiquitin ligase regulates PML-induced senescence in Myc-driven lymphomagenesis. Blood, 2012, 120, 822-832.	0.6	50
128	RAD21 cohesin overexpression is a prognostic and predictive marker exacerbating poor prognosis in KRAS mutant colorectal carcinomas. British Journal of Cancer, 2014, 110, 1606-1613.	2.9	50
129	Breast ductal carcinoma in situ carry mutational driver events representative of invasive breast cancer. Modern Pathology, 2017, 30, 952-963.	2.9	50
130	Multiplexed transcriptome analysis to detect ALK, ROS1 and RET rearrangements in lung cancer. Scientific Reports, 2017, 7, 42259.	1.6	49
131	Adrenomedullin and CGRP interact with endogenous calcitonin-receptor-like receptor in endothelial cells and induce its desensitisation by different mechanisms. Journal of Cell Science, 2006, 119, 910-922.	1.2	48
132	Expression of the forkhead transcription factor FOXP1 is associated with that of estrogen receptorÎ² in primary invasive breast carcinomas. Breast Cancer Research and Treatment, 2008, 111, 453-459.	1.1	48
133	Emerging entities in <scp>NUTM1</scp>â€rearranged neoplasms. Genes Chromosomes and Cancer, 2020, 59, 375-385.	1.5	47
134	The connection between lymphangiogenic signalling and prostaglandin biology: A missing link in the metastatic pathway. Oncotarget, 2012, 3, 893-906.	0.8	47
135	Plasminogen activator inhibitor-1 as a measure of vascular remodelling in breast cancer. Journal of Pathology, 2001, 195, 236-243.	2.1	45
136	The expression of the ubiquitin ligase SIAH2 (seven in absentia homolog 2) is mediated through gene copy number in breast cancer and is associated with a basal-like phenotype and p53 expression. Breast Cancer Research, 2011, 13, R19.	2.2	45
137	Enhanced RAD21 cohesin expression confers poor prognosis in BRCA2 and BRCAX, but not BRCA1 familial breast cancers. Breast Cancer Research, 2012, 14, R69.	2.2	45
138	Applicability of Next Generation Sequencing Technology in Microsatellite Instability Testing. Genes, 2015, 6, 46-59.	1.0	45
139	The E3-ligase E6AP Represses Breast Cancer Metastasis via Regulation of ECT2-Rho Signaling. Cancer Research, 2016, 76, 4236-4248.	0.4	45
140	HIF-1Î± stimulates aromatase expression driven by prostaglandin E2 in breast adipose stroma. Breast Cancer Research, 2013, 15, R30.	2.2	44
141	A phase Ib/II translational study of sunitinib with neoadjuvant radiotherapy in soft-tissue sarcoma. British Journal of Cancer, 2014, 111, 2254-2261.	2.9	44
142	Angiogenin is up-regulated in the nucleus and cytoplasm in human primary breast carcinoma and is associated with markers of hypoxia but not survival. Journal of Pathology, 2005, 205, 585-591.	2.1	43
143	Male breast cancer: an update. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2022, 480, 85-93.	1.4	43
144	A randomized controlled trial investigating the effects of celecoxib in patients with localized prostate cancer. Anticancer Research, 2009, 29, 1483-8.	0.5	43

#	Article	IF	Citations
145	Detection of the transforming AKT1 mutation E17K in non-small cell lung cancer by high resolution melting. BMC Research Notes, 2008, 1, 14.	0.6	42
146	Cytoplasmic location of factor-inhibiting hypoxia-inducible factor is associated with an enhanced hypoxic response and a shorter survival in invasive breast cancer. Breast Cancer Research, 2007, 9, R89.	2.2	41
147	Leukocyte adhesion-GPCR EMR2 is aberrantly expressed in human breast carcinomas and is associated with patient survival. Oncology Reports, 2011, 25, 619-27.	1.2	41
148	Expression of theforkhead transcription factor FOXP1 is associated both with hypoxia inducible factors (HIFs) and the Androgen receptor in prostate cancer but is not directly regulated by Androgens or hypoxia. Prostate, 2007, 67, 1091-1098.	1.2	40
149	RANKL-dependent and RANKL-independent mechanisms of macrophage-osteoclast differentiation in breast cancer. Breast Cancer Research and Treatment, 2007, 105, 7-16.	1.1	40
150	Gastric HER2 Testing Study (GaTHER). American Journal of Surgical Pathology, 2012, 36, 577-582.	2.1	40
151	Cohesin Rad21 Mediates Loss of Heterozygosity and Is Upregulated via Wnt Promoting Transcriptional Dysregulation in Gastrointestinal Tumors. Cell Reports, 2014, 9, 1781-1797.	2.9	40
152	Copy number analysis of ductal carcinoma in situ with and without recurrence. Modern Pathology, 2015, 28, 1174-1184.	2.9	40
153	Copy number analysis by low coverage whole genome sequencing using ultra low-input DNA from formalin-fixed paraffin embedded tumor tissue. Genome Medicine, 2016, 8, 121.	3.6	39
154	Breast Cancer Polygenic Risk Score and Contralateral Breast Cancer Risk. American Journal of Human Genetics, 2020, 107, 837-848.	2.6	39
155	Ductal carcinoma inÂsitu â€“ update on risk assessment and management. Histopathology, 2016, 68, 96-109.	1.6	38
156	Targeting Mdmx to treat breast cancers with wild-type p53. Cell Death and Disease, 2015, 6, e1821-e1821.	2.7	37
157	Breast lesions of uncertain malignant nature and limited metastatic potential: proposals to improve their recognition and clinical management. Histopathology, 2016, 68, 45-56.	1.6	37
158	Genome-wide functional analysis reveals central signaling regulators of lymphatic endothelial cell migration and remodeling. Science Signaling, 2017, 10, .	1.6	37
159	Profound MEK inhibitor response in a cutaneous melanoma harboring a GOLGA4-RAF1 fusion. Journal of Clinical Investigation, 2019, 129, 1940-1945.	3.9	37
160	Expression of cathepsin D and estrogen receptor in male breast carcinoma. Human Pathology, 1993, 24, 148-151.	1.1	36
161	A multisite blinded study for the detection of BRAF mutations in formalin-fixed, paraffin-embedded malignant melanoma. Scientific Reports, 2013, 3, 1659.	1.6	36
162	Oestrogen receptor and epidermal growth factor receptor expression in male breast carcinoma. Journal of Pathology, 1992, 166, 13-18.	2.1	35

#	Article	IF	Citations
163	Synergistic activity of letrozole and sorafenib on breast cancer cells. Breast Cancer Research and Treatment, 2010, 124, 79-88.	1.1	35
164	Triple Negative Breast Cancers Have a Reduced Expression of DNA Repair Genes. PLoS ONE, 2013, 8, e66243.	1.1	35
165	Lessons learnt from implementation of a Lynch syndrome screening program for patients with gynaecological malignancy. Pathology, 2017, 49, 457-464.	0.3	34
166	DNA methylation profiling of phyllodes and fibroadenoma tumours of the breast. Breast Cancer Research and Treatment, 2010, 124, 555-565.	1.1	33
167	CCL27/CCL28â€“CCR10 Chemokine Signaling Mediates Migration of Lymphatic Endothelial Cells. Cancer Research, 2019, 79, 1558-1572.	0.4	33
168	COX-2 expression is predictive for early relapse and aromatase inhibitor resistance in patients with ductal carcinoma in situ of the breast, and is a target for treatment. British Journal of Cancer, 2014, 111, 46-54.	2.9	32
169	<scp>MDM4</scp> is a rational target for treating breast cancers with mutant p53. Journal of Pathology, 2017, 241, 661-670.	2.1	32
170	Clinical implications of prospective genomic profiling of metastatic breast cancer patients. Breast Cancer Research, 2020, 22, 91.	2.2	32
171	Frequency of Fibroblast Growth Factor Receptor 1 gene amplification in oral tongue squamous cell carcinomas and associations with clinical features and patient outcome. Oral Oncology, 2013, 49, 576-581.	0.8	30
172	Restoration of tumor suppression in prostate cancer by targeting the E3 ligase E6AP. Oncogene, 2016, 35, 6235-6245.	2.6	30
173	Cost-effectiveness of precision medicine in the fourth-line treatment of metastatic lung adenocarcinoma: An early decision analytic model of multiplex targeted sequencing. Lung Cancer, 2017, 107, 22-35.	0.9	30
174	The number of regulatory T cells in prostate cancer is associated with the androgen receptor and hypoxia-inducible factor (HIF)-2Î± but not HIF-1Î±. Prostate, 2007, 67, 623-629.	1.2	29
175	Assessing HER2 amplification in breast cancer: findings from the Australian In Situ Hybridization Program. Breast Cancer Research and Treatment, 2012, 134, 617-624.	1.1	29
176	Combination of letrozole, metronomic cyclophosphamide and sorafenib is well-tolerated and shows activity in patients with primary breast cancer. British Journal of Cancer, 2015, 112, 52-60.	2.9	29
177	Langerhans cells in human lung tumours: an immunohistological study. Histopathology, 1989, 14, 269-275.	1.6	28
178	A high-throughput protocol for mutation scanning of the BRCA1 and BRCA2genes. BMC Cancer, 2011, 11, 265.	1.1	27
179	EGFR mutations in exons 18â€“21 in sporadic breast cancer. Annals of Oncology, 2007, 18, 203-205.	0.6	26
180	Combined Tumor Sequencing and Case-Control Analyses of RAD51C in Breast Cancer. Journal of the National Cancer Institute, 2019, 111, 1332-1338.	3.0	26

#	Article	IF	Citations
181	SP142 PD-L1 Scoring Shows High Interobserver and Intraobserver Agreement in Triple-negative Breast Carcinoma But Overall Low Percentage Agreement With Other PD-L1 Clones SP263 and 22C3. American Journal of Surgical Pathology, 2021, 45, 1108-1117.	2.1	26
182	Absence of retroviral vector-mediated transformation of gene-modified T cells after long-term engraftment in mice. Gene Therapy, 2008, 15, 1056-1066.	2.3	25
183	Loss of PML cooperates with mutant p53 to drive more aggressive cancers in a gender-dependent manner. Cell Cycle, 2013, 12, 1722-1731.	1.3	25
184	PathOS: a decision support system for reporting high throughput sequencing of cancers in clinical diagnostic laboratories. Genome Medicine, 2017, 9, 38.	3.6	25
185	Invasion in breast lesions: the role of the epithelialâ€“stroma barrier. Histopathology, 2018, 72, 1075-1083.	1.6	25
186	Interobserver variability in upfront dichotomous histopathological assessment of ductal carcinoma in situ of the breast: the DCISion study. Modern Pathology, 2020, 33, 354-366.	2.9	25
187	E6AP promotes prostate cancer by reducing p27 expression. Oncotarget, 2017, 8, 42939-42948.	0.8	25
188	The prolyl hydroxylase enzymes are positively associated with hypoxia-inducible factor-1Î± and vascular endothelial growth factor in human breast cancer and alter in response to primary systemic treatment with epirubicin and tamoxifen. Breast Cancer Research, 2011, 13, R16.	2.2	24
189	VEGF-D promotes pulmonary oedema in hyperoxic acute lung injury. Journal of Pathology, 2016, 239, 152-161.	2.1	24
190	Reduced abundance of the E3 ubiquitin ligase E6AP contributes to decreased expression of the INK4/ARF locus in nonâ€“small cell lung cancer. Science Signaling, 2017, 10, .	1.6	24
191	Nuclear HIF1A expression is strongly prognostic in sporadic but not familial male breast cancer. Modern Pathology, 2014, 27, 1223-1230.	2.9	23
192	Megakaryocytes in myelodysplasia: an immunohistochemical study on bone marrow trephines. Histopathology, 1990, 17, 69-74.	1.6	22
193	PIK3CA mutations are frequently observed in BRCAX but not BRCA2-associated male breast cancer. Breast Cancer Research, 2013, 15, R69.	2.2	22
194	The G-Proteinâ€“Coupled Receptor CLR Is Upregulated in an Autocrine Loop with Adrenomedullin in Clear Cell Renal Cell Carcinoma and Associated with Poor Prognosis. Clinical Cancer Research, 2013, 19, 5740-5748.	3.2	22
195	A Fully Human Inhibitory Monoclonal Antibody to the Wnt Receptor RYK. PLoS ONE, 2013, 8, e75447.	1.1	22
196	Mutational profiling of familial male breast cancers reveals similarities with luminal A female breast cancer with rare TP53 mutations. British Journal of Cancer, 2014, 111, 2351-2360.	2.9	22
197	Expression of E6AP and PML predicts for prostate cancer progression and cancer-specific death. Annals of Oncology, 2014, 25, 2392-2397.	0.6	22
198	Large genomic rearrangements in the familial breast and ovarian cancer gene BRCA1 are associated with an increased frequency of high risk features. Familial Cancer, 2015, 14, 287-295.	0.9	22

#	Article	IF	Citations
199	Cisplatin Increases Sensitivity to FGFR Inhibition in Patient-Derived Xenograft Models of Lung Squamous Cell Carcinoma. Molecular Cancer Therapeutics, 2017, 16, 1610-1622.	1.9	22
200	An Immunohistochemical and Prognostic Evaluation of Cathepsin D Expression in 105 Bladder Carcinomas. Journal of Urology, 1995, 154, 237-241.	0.2	21
201	Expression of BNIP3 correlates with hypoxiaâ€inducible factor (HIF)â€1Î±, HIFâ€2Î± and the androgen receptor in prostate cancer and is regulated directly by hypoxia but not androgens in cell lines. Prostate, 2008, 68, 336-343.	1.2	21
202	SDH-deficient renal cell carcinoma associated with biallelic mutation in succinate dehydrogenase A: comprehensive genetic profiling and its relation to therapy response. Npj Precision Oncology, 2018, 2, 9.	2.3	21
203	Atypical ductal hyperplasia is a multipotent precursor of breast carcinoma. Journal of Pathology, 2019, 248, 326-338.	2.1	21
204	Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses. Modern Pathology, 2021, 34, 194-206.	2.9	21
205	Breast Tissue Composition and Immunophenotype and Its Relationship with Mammographic Density in Women at High Risk of Breast Cancer. PLoS ONE, 2015, 10, e0128861.	1.1	20
206	DNA methylation in ductal carcinoma in situof the breast. Breast Cancer Research, 2013, 15, 206.	2.2	19
207	Differential expression of immunohistochemical markers in primary lung and breast cancers enriched for tripleâ€negative tumours. Histopathology, 2016, 68, 367-377.	1.6	19
208	RAF1 rearrangements are common in pancreatic acinar cell carcinomas. Modern Pathology, 2020, 33, 1811-1821.	2.9	19
209	The genetic architecture of breast papillary lesions as a predictor of progression to carcinoma. Npj Breast Cancer, 2020, 6, 9.	2.3	19
210	Methylation profiling of ductal carcinoma in situand its relationship to histopathological features. Breast Cancer Research, 2014, 16, 423.	2.2	18
211	Low-grade fibromatosis-like spindle cell carcinomas of the breast are molecularly exiguous. Journal of Clinical Pathology, 2015, 68, 362-367.	1.0	18
212	GATA3 expression in tripleâ€negative breast cancers. Histopathology, 2017, 71, 63-71.	1.6	18
213	BRAF Signaling Inhibition in Glioblastoma: Which Clinical Perspectives?. Frontiers in Oncology, 2021, 11, 772052.	1.3	18
214	A multiplex endpoint RT-PCR assay for quality assessment of RNA extracted from formalin-fixed paraffin-embedded tissues. BMC Biotechnology, 2010, 10, 89.	1.7	17
215	CNspector: a web-based tool for visualisation and clinical diagnosis of copy number variation from next generation sequencing. Scientific Reports, 2019, 9, 6426.	1.6	17
216	Determinants of variability of five programmed death ligand-1 immunohistochemistry assays in non-small cell lung cancer samples. Oncotarget, 2018, 9, 6841-6851.	0.8	17

#	Article	IF	Citations
217	Where and by Whom Should Gastric Cancer HER2/neu Status Be Assessed?: Lessons From Breast Cancer. Archives of Pathology and Laboratory Medicine, 2011, 135, 693-695.	1.2	17
218	Dihydropyrimidine Dehydrogenase Deficiency and Implementation of Upfront<scp>DPYD</scp>Genotyping. Clinical Pharmacology and Therapeutics, 2022, 112, 791-802.	2.3	17
219	Aberrant DNA methylation but not mutation of CITED4 is associated with alteration of HIF-regulated genes in breast cancer. Breast Cancer Research and Treatment, 2011, 130, 319-329.	1.1	16
220	The predictive ability of the 313 variantâ€“based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant. Genetics in Medicine, 2021, 23, 1726-1737.	1.1	16
221	DNA methylation analysis of the HIFâ€1Î± prolyl hydroxylase domain genes PHD1, PHD2, PHD3 and the factor inhibiting HIF gene FIH in invasive breast carcinomas. Histopathology, 2010, 57, 451-460.	1.6	15
222	kConFab: A Familial Breast Cancer Consortium Facilitating Research and Translational Oncology. Journal of the National Cancer Institute Monographs, 2011, 2011, 79-81.	0.9	15
223	Pure anti-tumor effect of zoledronic acid in naÃ¯ve bone-only metastatic and locally advanced breast cancer: proof from the â€œbiological window therapyâ€. Breast Cancer Research and Treatment, 2014, 144, 113-121.	1.1	15
224	HER2 testing in advanced gastric and gastro-oesophageal cancer: analysis of an Australia-wide testing program. Pathology, 2017, 49, 575-581.	0.3	15
225	Molecular comparison of interval and screenâ€detected breast cancers. Journal of Pathology, 2019, 248, 243-252.	2.1	15
226	Multiomics medicine in oncology: assessing effectiveness, costâ€“effectiveness and future research priorities for the molecularly unique individual. Pharmacogenomics, 2013, 14, 1405-1417.	0.6	14
227	Assessment of DNA methylation profiling and copy number variation as indications of clonal relationship in ipsilateral and contralateral breast cancers to distinguish recurrent breast cancer from a second primary tumour. BMC Cancer, 2015, 15, 669.	1.1	14
228	Interobserver variability in the assessment of stromal tumor-infiltrating lymphocytes (sTILs) in triple-negative invasive breast carcinoma influences the association with pathological complete response: the IVITA study. Modern Pathology, 2021, 34, 2130-2140.	2.9	14
229	Regulation of Hepatocyte Growth Factor Activator Inhibitor 2 by Hypoxia in Breast Cancer. Clinical Cancer Research, 2007, 13, 550-558.	3.2	13
230	No evidence for promoter region methylation of the succinate dehydrogenase and fumarate hydratase tumour suppressor genes in breast cancer. BMC Research Notes, 2009, 2, 194.	0.6	13
231	Anti-angiogenic effect of tamoxifen combined with epirubicin in breast cancer patients. Breast Cancer Research and Treatment, 2010, 123, 795-804.	1.1	13
232	Mammographically dense human breast tissue stimulates MCF10DCIS.com progression to invasive lesions and metastasis. Breast Cancer Research, 2016, 18, 106.	2.2	13
233	Mapping the EORTC-QLQ-C30 to the EQ-5D-3L: An Assessment of Existing and Newly Developed Algorithms. Medical Decision Making, 2018, 38, 954-967.	1.2	13
234	Metaplastic carcinomas of the breast without evidence of epithelial differentiation: a diagnostic approach for management. Histopathology, 2021, 78, 759-771.	1.6	13

#	Article	IF	Citations
235	LRH-1 expression patterns in breast cancer tissues are associated with tumour aggressiveness. Oncotarget, 2017, 8, 83626-83636.	0.8	13
236	Comparative microRNA profiling of sporadic and BRCA1 associated basal-like breast cancers. BMC Cancer, 2015, 15, 506.	1.1	12
237	Survival difference according to mutation status in a prospective cohort study of Australian patients with metastatic nonâ€smallâ€cell lung carcinoma. Internal Medicine Journal, 2018, 48, 37-44.	0.5	12
238	A MXI1-NUTM1 fusion protein with MYC-like activity suggests a novel oncogenic mechanism in a subset of NUTM1-rearranged tumors. Laboratory Investigation, 2021, 101, 26-37.	1.7	12
239	In vitro and inâ€‰vivo drug screens of tumor cells identify novel therapies for highâ€risk child cancer. EMBO Molecular Medicine, 2022, 14, e14608.	3.3	12
240	Second malignant tumors detected by needle aspiration cytology. Cancer, 1983, 52, 699-706.	2.0	11
241	More About: Tumor Angiogenesis as a Prognostic Assay for Invasive Ductal Breast Carcinoma. Journal of the National Cancer Institute, 2000, 92, 161-162.	3.0	11
242	Loss of STARD10 expression identifies a group of poor prognosis breast cancers independent of HER2/Neu and triple negative status. International Journal of Cancer, 2010, 126, 1445-1453.	2.3	11
243	Establishment of the Australian In Situ Hybridization Program for the Assessment of HER2 Amplification in Breast Cancer. Diagnostic Molecular Pathology, 2010, 19, 187-193.	2.1	11
244	Antitumor activities and onâ€target toxicities mediated by a TRAIL receptor agonist following cotreatment with panobinostat. International Journal of Cancer, 2011, 128, 2735-2747.	2.3	11
245	A Prospective Pathologic Study to Define the Clinical Target Volume for Partial Breast Radiation Therapy in Women With Early Breast Cancer. International Journal of Radiation Oncology Biology Physics, 2012, 84, 1116-1122.	0.4	11
246	National Working Group Meeting on ALK diagnostics in lung cancer. Asia-Pacific Journal of Clinical Oncology, 2014, 10, 11-17.	0.7	11
247	Immunomodulation by MYB is associated with tumor relapse in patients with early stage colorectal cancer. OncoImmunology, 2016, 5, e1149667.	2.1	11
248	ASCO/CAP 2018 breast cancer HER2 testing guidelines: summary of pertinent recommendations for practice in Australia. Pathology, 2019, 51, 345-348.	0.3	11
249	E6AP Promotes a Metastatic Phenotype in Prostate Cancer. IScience, 2019, 22, 1-15.	1.9	11
250	Re: Tumor Angiogenesis as a Prognostic Assay for Invasive Ductal Breast Carcinoma. Journal of the National Cancer Institute, 1995, 87, 1798-1799.	3.0	10
251	Correlation of Ataxia-Telangiectasia-Mutated (ATM) gene loss with outcome in head and neck squamous cell carcinoma. Oral Oncology, 2012, 48, 698-702.	0.8	10
252	HER2 status in gastric/gastro-oesophageal junctional cancers: should determination of gene amplification by SISH use HER2 copy number or HER2:CEP17 ratio?. Pathology, 2014, 46, 184-187.	0.3	10

#	Article	IF	Citations
253	Determining HER2 (ERBB2) amplification status in women with breast cancer: final results from the Australian in situ hybridisation program. Pathology, 2016, 48, 535-542.	0.3	10
254	BRCA2 carriers with male breast cancer show elevated tumour methylation. BMC Cancer, 2017, 17, 641.	1.1	10
255	Microscopic Assessment of Angiogenesis in Tumors. , 2001, 46, 029-046.		9
256	Assessing Tumor Angiogenesis in Histological Samples. Methods in Molecular Biology, 2009, 467, 55-78.	0.4	9
257	Nuclear Localization of Factor Inhibitor Hypoxia-Inducible Factor in Prostate Cancer Is Associated With Poor Prognosis. Journal of Urology, 2011, 185, 1513-1518.	0.2	9
258	Contribution of large genomic BRCA1 alterations to early-onset breast cancer selected for family history and tumour morphology: a report from The Breast Cancer Family Registry. Breast Cancer Research, 2011, 13, R14.	2.2	9
259	Targeting fibroblast growth factor receptor in breast cancer: a promise or a pitfall?. Expert Opinion on Therapeutic Targets, 2014, 18, 665-678.	1.5	9
260	Cousins not twins: intratumoural and intertumoural heterogeneity in syndromic neuroendocrine tumours. Journal of Pathology, 2017, 242, 273-283.	2.1	9
261	Evaluation of Crizotinib Treatment in a Patient With Unresectable GOPC-ROS1 Fusion Agminated Spitz Nevi. JAMA Dermatology, 2021, 157, 836-841.	2.0	9
262	â€œCancer 2015â€: A Prospective, Population-Based Cancer Cohortâ€”Phase 1: Feasibility of Genomics-Guided Precision Medicine in the Clinic. Journal of Personalized Medicine, 2015, 5, 354-369.	1.1	8
263	Australian consensus statement for best practice ROS1 testing in advanced non-small cell lung cancer. Pathology, 2019, 51, 673-680.	0.3	8
264	ALK-Rearranged Non-Small Cell Lung Cancer in 2020: Real-World Triumphs in an Era of Multigeneration ALK-Inhibitor Sequencing Informed by Drug Resistance Profiling. Oncologist, 2020, 25, 641-649.	1.9	8
265	Improved next-generation sequencing pre-capture library yields and sequencing parameters using on-bead PCR. BioTechniques, 2020, 68, 48-51.	0.8	8
266	Quantitative Angiogenesis in Breast Cancer. , 2006, 120, 161-188.		7
267	Molecular Oncology and the Neoadjuvant Setting: the Perfect Blend for Treatment Personalization and Clinical Trial Design. Journal of the National Cancer Institute Monographs, 2011, 2011, 67-70.	0.9	7
268	Altered significance of <scp>D</scp>'<scp>A</scp>mico risk classification in patients with prostate cancer linked to a familial breast cancer (k<scp>C</scp>on<scp>F</scp>ab) cohort. BJU International, 2015, 116, 207-212.	1.3	7
269	Immune molecular profiling of a multiresistant primary prostate cancer with a neuroendocrine-like phenotype: a case report. BMC Urology, 2020, 20, 171.	0.6	7
270	Novel RET Fusion RET-SEPTIN9 Predicts Response to Selective RET Inhibition With Selpercatinib in Malignant Pheochromocytoma. JCO Precision Oncology, 2021, 5, 1160-1165.	1.5	7

#	Article	IF	Citations
271	Hypoxia-related biological markers as predictors of epirubicin-based treatment responsiveness and resistance in locally advanced breast cancer. Oncotarget, 2017, 8, 78870-78881.	0.8	7
272	Tumour mutational burden: an overview for pathologists. Pathology, 2022, 54, 249-253.	0.3	7
273	Positron Emission Tomography and Neoadjuvant Therapy of Breast Cancer. Journal of the National Cancer Institute Monographs, 2011, 2011, 111-115.	0.9	6
274	Predictive Immunohistochemical Biomarkers in the Context of Neoadjuvant Therapy for Breast Cancer. Journal of the National Cancer Institute Monographs, 2011, 2011, 99-102.	0.9	6
275	High grade prostatic intraepithelial neoplasia does not display loss of heterozygosity at the mutation locus in BRCA2 mutation carriers with aggressive prostate cancer. BJU International, 2012, 110, E1181-6.	1.3	6
276	HER2-positive breast cancer metastatic to intracranial meningioma: a case report. Journal of Clinical Pathology, 2013, 66, 633-634.	1.0	6
277	Controversies in the management of gastrointestinal stromal tumors. Asia-Pacific Journal of Clinical Oncology, 2014, 10, 216-227.	0.7	6
278	<scp>KRAS</scp> mutation testing of metastatic colorectal cancer in <scp>A</scp>ustralia: Where are we at?. Asia-Pacific Journal of Clinical Oncology, 2014, 10, 261-265.	0.7	6
279	Effect of Primary Letrozole Treatment on Tumor Expression of mTOR and HIF-1Â and Relation to Clinical Response. Journal of the National Cancer Institute Monographs, 2015, 2015, 64-66.	0.9	6
280	Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with T2 to T4, N0 and N1 breast cancer. Breast, 2016, 29, 55-61.	0.9	6
281	The fibrinolysis inhibitor Î±₂-antiplasmin restricts lymphatic remodelling and metastasis in a mouse model of cancer. Growth Factors, 2017, 35, 61-75.	0.5	6
282	Exploring the feasibility and utility of exomeâ€scale tumour sequencing in a clinical setting. Internal Medicine Journal, 2018, 48, 786-794.	0.5	6
283	Transcriptome of Male Breast Cancer Matched with Germline Profiling Reveals Novel Molecular Subtypes with Possible Clinical Relevance. Cancers, 2021, 13, 4515.	1.7	6
284	Appraisal of the technologies and review of the genomic landscape of ductal carcinoma in situ of the breast. Breast Cancer Research, 2015, 17, 80.	2.2	5
285	Clinical cancer genomic analysis: data engineering required. Lancet Oncology, The, 2015, 16, 1015-1017.	5.1	5
286	MEK Inhibitor Therapy in Carcinomas With RAF1 Fusions: Inferior Response in a Patient With Pancreatic Acinar Cell Carcinoma. JCO Precision Oncology, 2019, 3, 1-2.	1.5	5
287	Canary: an atomic pipeline for clinical amplicon assays. BMC Bioinformatics, 2017, 18, 555.	1.2	4
288	Recurrent SPECC1Lâ€“NTRK fusions in pediatric sarcoma and brain tumors. Journal of Physical Education and Sports Management, 2020, 6, a005710.	0.5	4

#	Article	IF	Citations
289	The TP53 mutation rate differs in breast cancers that arise in women with high or low mammographic density. Npj Breast Cancer, 2020, 6, 34.	2.3	4
290	Blood vessel invasion and other variables as predictors of long-term survival in Japanese and British patients with primary invasive breast cancer. International Journal of Clinical and Experimental Pathology, 2014, 7, 7967-78.	0.5	4
291	Consensus approaches to best practice management of gastrointestinal stromal tumors. Asia-Pacific Journal of Clinical Oncology, 2008, 4, 188-198.	0.7	3
292	Assessing Tumor Angiogenesis in Histological Samples. Methods in Molecular Biology, 2016, 1430, 3-33.	0.4	3
293	BRAF mutation testing for patients diagnosed with stage III or stage IV melanoma: practical guidance for the Australian setting. Pathology, 2022, 54, 6-19.	0.3	3
294	TRACEBACK: Testing of Historical Tubo-Ovarian Cancer Patients for Hereditary Risk Genes as a Cancer Prevention Strategy in Family Members. Journal of Clinical Oncology, 2022, , JCO2102108.	0.8	3
295	Does cyclin D1 discriminate between BRCA2 and BRCAX breast cancers?. Histopathology, 2009, 55, 625-626.	1.6	2
296	No evidence for DNA methylation of von Hippel-Lindau ubiquitin ligase complex genes in breast cancer. Breast Cancer Research and Treatment, 2010, 124, 853-856.	1.1	2
297	The molecular characterisation of unusual subcutaneous spindle cell lesion of breast. Journal of Clinical Pathology, 2012, 65, 746-750.	1.0	2
298	Metastatic gastrointestinal stromal tumour of the ileum with dual primary c-KIT missence mutations. Pathology, 2013, 45, 604-606.	0.3	2
299	Precision oncology using a clinicianâ€directed, tailored approach to molecular profiling. Asia-Pacific Journal of Clinical Oncology, 2018, 14, 84-90.	0.7	2
300	Would the combination of everolimus with endocrine-therapy help in FGFR2 positive serous endometrial cancer?. Oncoscience, 2015, 2, 567-569.	0.9	2
301	Findings from precision oncology in the clinic: rare, novel variants are a significant contributor to scaling molecular diagnostics. BMC Medical Genomics, 2022, 15, 70.	0.7	2
302	Clinical validation and implementation of droplet digital PCR for the detection of BRAF mutations from cell-free DNA. Pathology, 2022, 54, 772-778.	0.3	2
303	Molecular profiling in colorectal cancer: current state of play and future directions. Colorectal Cancer, 2014, 3, 41-56.	0.8	1
304	Cancer 2015: a longitudinal whole-of-system study of genomic cancer medicine. Drug Discovery Today, 2015, 20, 1429-1432.	3.2	1
305	Reply to the Baaderâ€“Meinhof phenomenon in ductal carcinoma in situ of the breast. Histopathology, 2016, 69, 523-524.	1.6	1
306	Is it time for everolimus-based combination in castration-resistant prostate cancer?. Future Oncology, 2016, 12, 1849-1852.	1.1	1

#	Article	IF	Citations
307	Response to Editorial:ÂTheÂPD-L1 Immunohistochemistry Biomarker: Two Steps Forward, One Step Back?. Journal of Thoracic Oncology, 2018, 13, e185-e186.	0.5	1
308	Using Genomic Sequencing to Explain an Exceptional Response to Therapy in a Malignant Phyllodes Tumor. JCO Precision Oncology, 2020, 4, 1263-1266.	1.5	1
309	EGFR mutation profile in Australian patients with non-small cell lung cancer. Pathology, 2021, 53, 933-936.	0.3	1
310	Angiogenesis in Mammary Tumors: Quantitation and Relation to Prognosis. , 2001, , 63-84.		1
311	Biobanking in Cancer Research. , 2016, , 27-49.		1
312	Diagnostic and Prognostic Significance of Tumor Angiogenesis. , 2002, , 151-176.		1
313	ROS1 rearrangements in non-small cell lung cancer: screening by immunohistochemistry using proportion of cells staining without intensity and excluding cases with MAPK pathway drivers improves test performance. Pathology, 2021, , .	0.3	1
314	Steroid Hormone and Oncoprotein Expression in Male Breast Carcinoma. Journal of Histotechnology, 1991, 14, 286-286.	0.2	0
315	BRCA1 associated breast cancers are frequently positive for ER and its cytoplasmic expression confers a poor prognosis. Pathology, 2009, 41, 51.	0.3	0
316	Diagnostic issues with significant tumour displacement in breast biopsies. Journal of Clinical Pathology, 2014, 67, 1110-1111.	1.0	0
317	In Response. Journal of Thoracic Oncology, 2015, 10, e85.	0.5	0
318	Neoadjuvant Model in Cancer Treatment: From Clinical Opportunity to Health-Care Utility. Journal of the National Cancer Institute Monographs, 2015, 2015, 1-3.	0.9	0
319	KRAS mutation testing in colorectal cancer: the model for molecular pathology testing in the future. Colorectal Cancer, 2016, 5, 73-80.	0.8	0